For potential clinical direction, targeting IL-35 in combination with therapies like PD-1/PD-L1 inhibitors, CAR-T cell therapy, or anti-angiogenic agents holds promise for improving GC treatment outcomes. This evidence concerns the gene CD274 and gastric cancer.